Publication Name	World Journal of Hepatology
Manuscript ID	3671
Country	Italy

Received	2013-05-14 08:20
Peer-Review Started	2013-05-14 15:03
To Make the First Decision	2013-05-23 17:19
Return for Revision	2013-05-24 10:01
Revised
Second Decision	2013-09-18 10:54
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-09-18 11:29
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-09-24 21:01
Typeset the Manuscript	2013-10-23 18:52
Publish the Manuscript Online	2013-10-25 08:47

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Gianni Testino and Paolo Borro
Funding Agency and Grant Number
Corresponding Author	Gianni Testino, MD, Department of Internal e Specialistic Medicine, Centro Alcologico Regionale–Regione Liguria, UO Alcologia e Patologie Correlate, Padiglione 10 (piano Terra), Piazzale R. Benzi 10, 16132 Genova, Italy. gianni.testino@hsanmartino.it
Key Words	Chemoprevention; Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma
Core Tip	Interferon (IFN) therapy has been reported to decrease the risk of hepatocellular carcinoma (HCC) and improve survival. The use of IFN in patients with hepatitis C virus (HCV) compensated cirrhosis reduces the negative clinical evolution independently of the type of the laboratoristic and virological response. In our experience, IFN therapy in HCV compensated cirrhosis is barely useful in the prevention of HCC, as cirrhosis itself represents a risk of cancer. It would probably be interesting to evaluate the efficacy of weekly low-dose pegylated (PEG)-IFN therapy in patients with HCV cirrhosis and to assess potential benefits of long-term PEG-IFN plus Ribavirin treatment.
Publish Date	2013-10-25 08:47
Citation	Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol 2013; 5(10): 521-527
URL	http://www.wjgnet.com/1948-5182/full/v5/i10/521.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i10.521

Full Article (PDF)	WJH-5-521.pdf
Manuscript File	3671-Review.edited.doc
Peer-review Report	3671-Peer reviews.pdf
Scientific Editor Work List	3671-Scientific editor work list.doc